High Serum FABP4 Levels are Negatively Associated with the Reversion from Prediabetes to Normal Glucose Tolerance: A 2-Year Retrospective Cohort Community Study

References

• Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997. doi:10.1136/bmj.m997
   PubMed Web of Science ®Google Scholar
• Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–2290. doi:10.1016/S0140-6736(12)60283-9
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305–312. doi:10.1016/j.diabres.2007.05.004
   PubMed Web of Science ®Google Scholar
• Hostalek U. Global epidemiology of prediabetes - present and future perspectives. Clin Diabetes Endocrinol. 2019;5(1):5. doi:10.1186/s40842-019-0080-0
   PubMedGoogle Scholar
• Li N, Lu C, Ma Y, et al. Factors associated with progression of different prediabetic status to Diabetes: a Community-based cohort study. Diabetes Res Clin Pract. 2022;184:109193. doi:10.1016/j.diabres.2022.109193
   Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866–875. doi:10.1016/S2213-8587(15)00291-0
   PubMed Web of Science ®Google Scholar
• Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54(2):300–307. doi:10.1007/s00125-010-1948-9
   PubMed Web of Science ®Google Scholar
• Haunerland NH, Spener F. Fatty acid-binding proteins–insights from genetic manipulations. Prog Lipid Res. 2004;43(4):328–349. doi:10.1016/j.plipres.2004.05.001
   PubMed Web of Science ®Google Scholar
• Li B, Hao J, Zeng J, Sauter ER. SnapShot: FABP Functions. Cell. 2020;182(4):1066–1066. doi:10.1016/j.cell.2020.07.027
   PubMed Web of Science ®Google Scholar
• Jin J, Hao J, Yi Y, Sauter E, Li B. Regulation of macrophage functions by FABP-mediated inflammatory and metabolic pathways. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(8):158964. doi:10.1016/j.bbalip.2021.158964
   Web of Science ®Google Scholar
• Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007;30(10):2667–2672. doi:10.2337/dc07-0413
   PubMed Web of Science ®Google Scholar
• Ning H, Tao H, Weng Z, Zhao X. Plasma fatty acid-binding protein 4 (FABP4) as a novel biomarker to predict gestational diabetes mellitus. Acta Diabetol. 2018;55(10):1089. doi:10.1007/s00592-016-0867-8
   Web of Science ®Google Scholar
• Tanaka M, Takahashi S, Higashiura Y, et al. Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. J Diabetes Investig. 2021;2021. doi:10.1111/jdi.13735
   Web of Science ®Google Scholar
• Xu A, Tso AW, Cheung BM, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation. 2007;115(12):1537–1543. doi:10.1161/CIRCULATIONAHA.106.647503
   Web of Science ®Google Scholar
• Nakamura R, Okura T, Fujioka Y, et al. Serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, A clinical study. PLoS One. 2017;12(6):e0179737. doi:10.1371/journal.pone.0179737
   Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi:10.1007/BF00280883
   PubMed Web of Science ®Google Scholar
• Colman PG, Thomas DW, Zimmet PZ, Welborn TA, Garcia-Webb P, Moore MP. New classification and criteria for diagnosis of diabetes mellitus. The Australasian working party on diagnostic criteria for diabetes mellitus. N Z Med J. 1999;112(1086):139–141.
   PubMedGoogle Scholar
• Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366(9491):1059–1062. doi:10.1016/S0140-6736(05)67402-8
   PubMed Web of Science ®Google Scholar
• Zhou BF; Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15(1):83–96.
   PubMed Web of Science ®Google Scholar
• Wang T, Lu J, Shi L, et al. Association of insulin resistance and β-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study. Lancet Diabetes Endocrinol. 2020;8(2):115–124. doi:10.1016/S2213-8587(19)30425-5
   Web of Science ®Google Scholar
• de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 2001;285(16):2109–2113. doi:10.1001/jama.285.16.2109
   PubMed Web of Science ®Google Scholar
• Bozorgmanesh M, Hadaegh F, Azizi F. A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Res Clin Pract. 2012;97(2):e34–e36. doi:10.1016/j.diabres.2012.04.018
   Web of Science ®Google Scholar
• Cabia B, Andrade S, Carreira MC, Casanueva FF, Crujeiras AB. A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis. Obes Rev. 2016;17(4):361–376. doi:10.1111/obr.12377
   PubMed Web of Science ®Google Scholar
• Boord JB, Maeda K, Makowski L, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004;110(11):1492–1498. doi:10.1161/01.CIR.0000141735.13202.B6
   PubMed Web of Science ®Google Scholar
• Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology. 2000;141(9):3388–3396. doi:10.1210/endo.141.9.7637
   PubMed Web of Science ®Google Scholar
• Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006;52(3):405–413. doi:10.1373/clinchem.2005.062463
   PubMed Web of Science ®Google Scholar
• Li S, Bi P, Zhao W, et al. Prognostic utility of fatty acid-binding protein 4 in patients with type 2 diabetes and acute ischemic stroke. Neurotox Res. 2018;33(2):309–315. doi:10.1007/s12640-017-9792-z
   PubMed Web of Science ®Google Scholar
• Trojnar M, Patro-Małysza J, Kimber-Trojnar Ż, Leszczyńska-Gorzelak B, Mosiewicz J. Associations between fatty acid-binding protein 4⁻a proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells. 2019;8(3):227. doi:10.3390/cells8030227
   PubMed Web of Science ®Google Scholar
• Liu G, Ding M, Chiuve SE, et al. Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: a 22-year prospective study. Arterioscler Thromb Vasc Biol. 2016;36(11):2259–2267. doi:10.1161/ATVBAHA.116.308320
   PubMed Web of Science ®Google Scholar
• Wang H, Cao J, Su JB, et al. Serum fatty acid-binding protein 4 levels and responses of pancreatic islet β-cells and α-cells in patients with type 2 diabetes. Diabetol Metab Syndr. 2021;13(1):70. doi:10.1186/s13098-021-00690-z
   Web of Science ®Google Scholar
• Li HL, Wu X, Xu A, Rl Hoo. A-FABP in metabolic diseases and the therapeutic implications: an update. Int J Mol Sci. 2021;22(17):9386. doi:10.3390/ijms22179386
   Web of Science ®Google Scholar
• Burak MF, Inouye KE, White A, et al. Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. Sci Transl Med. 2015;7(319):319ra205. doi:10.1126/scitranslmed.aac6336
   Web of Science ®Google Scholar